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A B S T R A C T
Introduction: XC8 (histamine glutarimide) is a novel agent which targets eosinophilic migration and mast cell
degranulation and has shown anti-asthmatic effects in animal studies.
Objective: The objective of this placebo-controlled phase 1 study was to assess the safety of oral XC8 and to
evaluate its pharmacokinetic and pharmacodynamic properties.
Methods: 32 healthy volunteers in three dose-escalation treatment groups (10mg [n= 8], 50mg [n= 8] and
200mg [n= 16]) were randomized in a 3:1 ratio to XC8 or placebo respectively. The subjects received a single
dose of the drug at Day 1 and then once-daily for 14 days (Days 8–21).
Results: No severe adverse events occurred. The number of adverse events was similar in the treatment arms
compared to placebo and all subjects completed the study as planned. No clinically significant changes occurred
in hematologic and biochemical blood tests in subjects receiving XC8. The pharmacokinetic data showed similar
dose and time dependent mean plasma XC8 concentrations after single (Day 1) and multiple (Day 21) dosing.
The mean maximum concentrations were 114–1993 ng/mL after single and 115–2089 ng/mL after multiple
dosing. The mean times to maximum concentration were 0.68–1.01 and 0.67–0.98 h, respectively. There was no
evidence for accumulation of XC8 after multiple dosing.
Conclusion: XC8 was safe and well tolerated. A phase 2 study is being performed to further evaluate the potential
role of XC8 in asthma treatment.
Trial registration: ClinicalTrials.gov, NCT02882217.
1. Introduction
Asthma is a chronic, common and heterogeneous airway disease
[1]. Asthma control is poor in more than 50% of patients and adherence
to inhalation therapies is low [2–4]. Eosinophilic airway inflammation
plays an integral part in the pathophysiology in all T2-high asthma
phenotypes [5,6]. Peripheral blood eosinophils (PBE) correlate with
airway inflammation, airway hyperresponsiveness and asthma severity
and are routinely measured to assess eosinophilic airway inflammation
[7–9].
XC8 (histamine glutarimide) is a novel anti-asthmatic agent which
targets eosinophilic migration and mast cell degranulation by inhibition
of maturation of chemokines (CCL2, CCL7, CCL8, CCL13). A previous
study has shown that XC8 reduces airway resistance and eosinophil
counts in bronchoalveolar lavage and lung tissue in sephadex induced
lung inflammation in rats and ovalbumin induced asthma in guinea pigs
[10].
This paper presents the results of a randomized, dose escalating,
placebo-controlled multi-center, phase-1 study performed to assess the
safety and tolerability of single and multiple doses of oral XC8 ad-
ministered in healthy volunteers. The secondary endpoints were eval-
uating pharmacokinetic (PK) and pharmacodynamic (PD) properties
after single and multiple dosing schedules.
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This was a randomized, placebo-controlled, dose-escalating, group-
sequential phase 1 study designed to assess the safety, tolerability and
PK of single and multiple doses of XC8 (http://clinicaltrials.gov iden-
tifier: NCT02882217). Subjects underwent a screening period of up to
14 days, during which their eligibility was assessed. Thirty-two healthy
subjects were allocated to 3 dosing groups (10, 50, and 200mg dosing)
and randomized to treatment with XC8 or placebo in a 3:1 ratio (6
subjects receiving 10 and 50mg XC8 and 2 placebo in treatment groups
1 and 2 and, and 12 subjects receiving 200mg XC8 and 4 placebo in
treatment group 3). Due to the dose escalating design (see 2.2 Study
conduct) investigators and subjects were double-blinded regarding the
randomization to active treatment and placebo, but not to the dosing
group.
Men and women aged 18–50 years in generally good health and
with a body mass index of 19–30 kg/m2 were included. Female subjects
of childbearing potential had to use a method of birth control with a
failure rate of less than 1% per year. A full list of inclusion and exclu-
sion criteria can be found in E-Supplement Tables 1 and 2
2.2. Study conduct
The study was conducted at two sites (Karl Landsteiner Institute for
experimental and clinical pneumology, Vienna, Austria; Fraunhofer
Institute for toxicology and experimental medicine [ITEM], Hannover,
Germany). Informed consent forms and study protocol were reviewed
and approved by the local ethics committees. Monitoring was per-
formed by FGK Clinical Research GmbH, Munich, Germany. The study
was conducted following local regulations, the Declaration of Helsinki
and Good Clinical Practice guidelines.
Starting with the lowest dose treatment group, subjects received a
single dose of XC8 or placebo on Day 1. After a wash-out period of 6
days, subjects received a once-daily dose for 14 subsequent days (Days
8–21). After safety data for all subjects in the treatment group were
collected for at least 7 days (Day 29), a dose escalation committee re-
viewed clinical safety and safety laboratory data provided by the in-
vestigators and recommended further actions regarding the dose esca-
lation of the next treatment group. If it was considered safe to proceed,
the next higher dose level treatment group was treated following the
same schedule as described for the lower dose level treatment group.
On Day 1 and Days 8–21, subjects had blood samples taken for PK
analyses immediately before, and 20 and 40min, and 1, 2, 4, 8, and
24 h after study drug administration. Follow-up visits were scheduled
on Days 29 and 36. Further blood samples were taken on Days 1, 2, 8,
and 22 to assess PBE. Safety assessments (safety laboratory, electro-
cardiogram and physical examination) were performed throughout the
screening, single-dosing, multiple-dosing and follow-up period.
2.3. Investigational product
The investigational product was administered orally in the morning
in film-coated tablets containing 10 or 100mg of XC8. XC8 substance
was produced and provided by FARMAK (Czech Republic). XC8 is a 1-
(2-(1H-Imidazol-4-yl)ethyl)piperidine-2,6-dione based on IUPAC no-
menclature. The investigational product was produced and released per
current European Good Manufacturing Practice regulations. Study
medication was stored below 25 °C and protected from light. To
maintain the blind, XC8 and the placebo tablets had identical appear-
ance, shape and color, as well as identical labeling and packaging.
2.4. Physical examination, vital signs and electrocardiogram
The physical examination included an assessment of the general
appearance, skin, head, eyes, ears, nose, throat, neck, lymph nodes,
chest, heart, abdomen, extremities, and nervous system. Vital signs
(respiratory rate, heart rate, blood pressure, and body temperature)
were measured in sitting position after the subject had rested for at least
5min. Twelve-lead electrocardiogram was performed following stan-
dard procedures and evaluated locally at screening, Day 1 pre-dose and
8 h post-dose, Day 2, Day 8 pre-dose and Days 22, 29 and 36.
2.5. Laboratory evaluations
The safety laboratory examinations consisted of a complete blood
count including leukocyte differential count, clinical chemistry in-
cluding electrolytes, kidney function tests and liver function tests, and
urinalysis. A complete list of all performed safety laboratory can be
found in E-Supplement Table 3. The safety laboratory studies were
performed immediately at the local study sites.
PK analysis was performed at Biopharm (Jilove u Prahy, Czech
Republic) using a validated high-performance liquid chromatography
tandem mass spectrometer method.
2.6. Data analysis
2.6.1. Baseline demographics
Baseline demographic data and medical history were summarized
descriptively.
2.6.2. Safety analysis
The analysis of adverse events (AE) was focused on treatment
emergent adverse events (TEAE), defined as AEs with onset after the
first intake of study medication. Serious TEAEs and TEAE related to the
study medication were listed separately. Pre-treatment-emergent AEs
were listed, also. AEs were classified using system organ classes (SOC)
and preferred terms (PT) as defined in the Medical Dictionary for
Regulatory Activities (MedDRA®) version 19.0. MedDRA® the Medical
Dictionary for Regulatory Activities terminology is the international
medical terminology developed under the auspices of the International
Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use.
Laboratory data, including hematology, clinical chemistry, and ur-
inalysis data, were summarized by dose group and visit. Changes from
Day 1 pre-dose to Day 2 and Day 8 pre-dose to later time points were
presented using shift tables (employing the categories ‘normal’, ‘ab-
normal, clinically not significant’, and ‘abnormal, clinically significant’)
and as absolute changes, if appropriate. Laboratory values were clas-
sified as abnormal if they were outside the local sites' laboratory re-
ference ranges (see E-Supplement Table 3). In case of abnormal values
investigators at the local site immediately assessed the change as either
clinically significant or not. Any clinically significantly abnormal re-
sults were listed separately. Vital signs and body temperatures were
summarized by visit. Results of physical examinations were listed. Shift
Tables were used to present changes from Day 1 pre-dose to Day 2, and
Day 8 pre-dose to any later time point using the categories ‘normal’,
‘abnormal, not clinically significant’, and ‘abnormal, clinically sig-
nificant’.
2.6.3. Pharmacokinetic data
Evaluated PK parameters were the area under the plasma con-
centration curve extrapolated to infinity (AUCinf), area under the
plasma concentration curve up to 24 h after the last study drug ad-
ministration (AUC0-24), area under the plasma concentration curve up
to last sampling time with concentration above the limit of quantifi-
cation (AUC0-tlast), maximum serum concentration (Cmax), last observed
quantifiable concentration (Clast), median time to Cmax (Tmax), elim-
ination half-life (t1/2), elimination rate (Kel), average concentration
over one dosing interval (Cav) and the accumulation ratio between Day
1 and Day 21 based on Cmax, AUC0-24, and AUCinf. PK parameters were
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calculated using non-compartmental analysis based on observed XC8
plasma concentrations and post-dose sampling times.
Cmax and Tmax were obtained directly from the measured con-
centrations. AUC0-tlast were calculated by the linear/log trapezoidal rule
up to the last measured concentration above the lower limit of quan-
tification. AUC0-24 was calculated by the linear/log trapezoidal rule up
to 24 h after study drug administration. Cav was computed as AUC0-24/τ,
where τ was the dosing interval obtained from the post-dose time of the
24-h sample. Kel was estimated by log-linear regression on the apparent
terminal elimination phase. AUCinf was extrapolated to infinity as
AUC0-tlast + Clast/Kel. The elimination half-life was calculated as t1/
2= ln(2)/Kel. The accumulation ratios were calculated based on Cmax.
The relationship between PK parameters and the nominal dose was
explored assuming a power model (PK = a × Dose b, which is
equivalent to log[PK] = log[a] + b × log[Dose]). This relationship
was evaluated for Cmax, AUC0-24 and AUCinf after single (Day 1) and
after multiple (Day 21) dosing. In line with the above equation, a linear
regression was applied between the logarithm of the individual PK
parameter and the logarithmic of the nominal dose. The dose-pro-
portionality of PK parameters was assessed based on the slope (b in the
above equation) estimate, with a slope significantly smaller or higher
than 1 indicating an increase of the PK parameters lower or higher than
expected from a dose-proportional relationship, respectively.
2.6.4. Pharmacodynamic data
Changes in PBE were summarized descriptively.
3. Results
3.1. Study population
All 32 screened subjects were randomized and received the study
medication. In treatment groups 1 and 2, 6 subjects each received active
treatment and 2 subjects each received placebo. In treatment group 3,
12 subjects received active treatment and 4 subjects received placebo.
All 32 subjects completed the study as scheduled. Baseline demographic
data are shown in Table 1. The median age was about 30 years, ranging
from 20 to 50 years. Although the median age was markedly higher in
the 50mg XC8 treatment group (48 years), the range (31–50) was
comparable to the other treatment groups and placebo. All subjects
were Caucasian. All subjects took the study medication per randomi-
zation and per protocol.
3.2. Safety analysis
3.2.1. Adverse events
A summary of TEAEs is given in Table 2. 54% of subjects treated
with XC8 and 75% of subjects treated with placebo experienced one or
more TEAE(s). The number of TEAEs which were assessed to be related
to the study medication by the investigators appeared to increase with
increasing XC8 dose (1 report in 1 subject receiving 10mg XC8, 4 re-
ports in 3 subjects receiving 50mg XC8, and 10 reports in 3 subjects
treated with 200mg XC8). None of the reported TEAEs were serious,
led to premature termination, or resulted in death. One subject treated
with 200mg XC8 had experienced a pre-treatment-emergent event
(upper respiratory tract infection). An overview of TEAEs by SOC and
PT is provided in Table 3. No difference between active treatment and
placebo or dose-dependency for XC8 was apparent. All TEAEs had re-
solved by Day 36.
3.2.2. Laboratory analysis
No shifts to clinically significantly abnormal values were observed
in hematology. No subject in any of the XC8 treatment groups had shifts
to clinically significantly abnormal values in the clinical chemistry la-
boratory. Two subjects treated with placebo had a shift from normal to
clinically significantly abnormal values in the clinical chemistry la-
boratory (see below) and one subject in the 200mg XC8 treatment group
had clinically significantly abnormal urinalysis, which was later diag-
nosed as cystitis (assessed as not related to the study medication, see
below).
One of the placebo-treated subjects had clinically significantly high
values in both blood creatine phosphokinase and aspartate amino-
transferase on Day 29, which were both reported as mild TEAEs with
relation to the study medication. Blood creatine phosphokinase had
increased from 56 U/L on Day 1 and from 55 U/L on Day 8–5095 U/L
on Day 29. On all assessments before Day 29, values were within the
normal range (≤168 U/L). The TEAE had resolved by Day 36.
Similarly, aspartate aminotransferase levels had increased from 25 U/L
on Day 1 and Day 8–126 U/L on Day 29. All assessments up until Day
29 were within the normal range (≤31 U/L). The TEAE had resolved by
Day 36.
The other placebo-treated subject had an increase in the blood
creatine phosphokinase on Day 8–726 U/L (Day 1: 191 U/L; normal
range<190 U/L), which was reported as moderate TEAE with no re-
lation to the study medication. The subject had a further increase in
creatine phosphokinase levels on Day 10–3268 U/L (1111 U/L in a
repeated measurement); all these increases were assessed as not clini-
cally significant. Creatine phosphokinase levels decreased to 347 U/L
by Day 15 and the TEAE was considered resolved.
One subject in the 200mg XC8 treatment group had clinically sig-
nificant abnormal urinalysis values for nearly all urinalysis parameters
from Day 15 onwards. Most of these parameters were already outside
the normal range but not clinically significant on Day 8 pre-dose. The
urinalysis parameters with a shift from normal or non-clinically sig-
nificantly abnormal to clinically significantly abnormal for this subject
after Day 15 included ketones, bilirubin, erythrocytes, leukocytes and
Table 1
Baseline demographics.
Placebo (N=8) 10mg XC8 (N=6) 50mg XC8 (N=6) 200mg XC8 (N=12) Total (N=32)
Sex
Male N (%)a 4 (50.0) 2 (33.3) 4 (66.7) 7 (58.3) 17 (53.1)
Female N (%)a 4 (50.0) 4 (66.7) 2 (33.3) 5 (41.7) 15 (46.9)
Age [years] Median 36.5 29.5 48.5 24.5 30.5
Range 23–48 27–50 31–50 20–39 20–50
Weight [kg] Median 81.2 86.6 77.5 78.0 80.6
Range 65.0–109.0 59.6–97.9 62.9–83.5 60.0–97.0 59.6–109.0
Height [cm] Median 176.0 180.0 176.0 174.5 177.5
Range 159–192 167–185 163–187 163–204 159–204
BMI [kg/m2] Median 25.6 25.9 24.2 23.5 24.3
Range 22.5–29.8 21.4–29.4 22.3–28.5 20.8–29.2 20.8–29.8
a Percentages are based on the total N in the analysis set. BMI=body mass index, N=number of subjects.
A. Renner, et al. Pulmonary Pharmacology & Therapeutics 59 (2019) 101852
3
bacteria. On Day 17, cystitis was reported that was assessed as not re-
lated to the study medication and may explain the abnormal urinalysis
results described above.
E-Supplement Table 4 shows the changes from normal to not
clinically significantly abnormal laboratory values.
3.2.3. Vital signs and electrocardiogram
No differences in vital signs were apparent between placebo and
active treatment or between doses of XC8. No shifts to clinically sig-
nificantly abnormal values were noted in the electrocardiogram.
3.2.4. Physical examination
In 4 subjects, abnormal findings were reported after intake of study
medication. In the 10mg XC8 group one subject had a discrete swelling
of cervical lymph nodes (Day 36). In the 200mg XC8 group one subject
had a red throat as part of a viral infection (Day 8) and another subject
had a left leg bruise from soccer (not related, Day 36). In the placebo
group one subject had mild wheezes over the right chest (Day 22).
3.3. Pharmacokinetic data
The plasma concentration-time profiles for XC8 on Day 1 and Day
21 are shown in Fig. 1. The concentration time curves show a similar
profile after single (Day 1) and multiple (Day 21) dosing. The exposure
(AUC) and peak concentration (Cmax) of XC8 showed an increase with
increasing dose. The median time to Cmax was 0.68–1.01 h after single
dosing (Day 1) and 0.67–0.98 h after multiple dosing (Day 21).
The mean accumulation ratios on Cmax, AUC0-24, or AUCinf were all
close to 1 (0.88–1.15), suggesting no accumulation of XC8 after multiple
dosing. The median elimination half-life increased with increasing dose
from about 1.8 h on Day 1 in the 10mg XC8 group to about 4.3 h on Day
1 in the 200mg XC8 group but did not show major differences between
multiple and single dosing. A summary of PK parameters for XC8 is shown
in Table 4. The analysis of dose-proportionality is shown in Table 5. As
indicated by slope at Day 1 included within the 95% CI, no significant
departure from dose-proportionality was observed after single adminis-
tration. After multiple dosing, a slight but significant (p=0.0058) over-
proportionality was observed for AUC0-24. As the magnitude of the de-
parture from dose-proportionality is very low (95% CI=1.04–1.21), the
over-proportionality is not expected to have any clinical relevance.
3.4. Pharmacodynamic data
No changes in PBE levels were apparent. Mean PBE levels stayed
below 4% at all times for all treatment groups.
4. Discussion
XC8 was well tolerated and safe at doses of 10, 50, and 200mg after
single and multiple 14-day administration. No deaths occurred, no
serious TEAEs were reported, and no TEAEs led to premature study
termination. All reported TEAEs were mild or moderate and had re-
solved by Day 36. No apparent difference in TEAE frequency was ob-
served between active dosing and placebo and no obvious dose-re-
lationship for XC8 was seen. The number of subjects reporting related
TEAEs appeared higher in the 200mg XC8 dose group, which may be
due to higher subject numbers in that dose group.
After oral administration, the drug was rapidly absorbed, and the
median maximum concentration was reached after 0.68–1.01 h after
single dosing. The median plasma elimination half-life of XC8 increased
Table 2
Summary of TEAEs.
Placebo (N=8) 10mg XC8 (N=6) 50mg XC8 (N=6) 200mg XC8 (N=12) Total (N=32)
Number of TEAEs 13 4 11 14 42
Number (%)a of related TEAEsb 7 (53.8) 1 (25.0) 4 (36.4) 10 (71.4) 22 (52.4)
Number (%)a of subjects with TEAEs 6 (75.0) 3 (50.0) 4 (66.7) 6 (50.0) 19 (59.4)
Number (%)a of subjects with related TEAEsb 3 (37.5) 1 (16.7) 3 (50.0) 3 (25.0) 10 (31.3)
N=number of subjects, TEAE= treatment-emergent adverse event.
a Percentages are based on the number of events in each treatment group.
b Assessed as related to the study medication.
Table 3
TEAEs by SOC and PT.
SOC (MedDRA) PT Number (%)a of subjects
Placebo (N=8) 10mg XC8 (N=6) 50mg XC8 (N=6) 200mg XC8 (N=12) Total (N=32)
Gastrointestinal disorders 1 (12.5) - 1 (16.7) 1 (8.3) 3 (9.4)
General disorders and administration site conditions 1 (12.5) - 1 (16.7) 2 (16.7) 4 (12.5)
Infections and infestations 2 (25.0) 1 (16.7) 2 (33.3) 4 (33.3) 9 (28.1)
Nasopharyngitis 2 (25.0) 1 (16.7) 2 (33.3) 1 (8.3) 6 (18.8)
Investigations 2 (25.0) - - - 2 (6.3)
Blood creatine phosphokiase increased- 2 (25.0) - - - 2 (6.3)
Musculoskeletal and connective tissue disorders - 1 (16.7) 1 (16.7) - 2 (6.3)
Nervous system disorders 2 (25.0) 1 (16.7) 3 (50.0) 1 (8.3) 7 (21.9)
Headache 2 (25.0) 1 (16.7) 3 (50.0) 1 (8.3) 7 (21.9)
Respiratory, thoracic and mediastinal disorders 2 (25.0) 1 (16.7) 1 (16.7) - 4 (12.5)
Total 6 (75.0) 3 (50.0) 4 (66.7) 6 (50.0) 19 (59.4)
Preferred terms are only displayed for TEAEs that were reported by≥2 subjects in the same treatment group. N=0 is shown as ‘-‘.
MedDRA=Medical Dictionary for Regulatory Activities, N= number of subjects, PT= preferred term, SOC= system organ class, TEAE= treatment-emergent
adverse event.
a Percentages are based on the number of subjects in each treatment group.
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with increasing dose from 1.8 h in the 10mg XC8 group to 4.3 h in the
200mg XC8 group after single dosing. There was a slight over-pro-
portionality after multiple dosing. This is not expected to be clinically
relevant.
The main limitation of this study is that the subjects were healthy,
non-asthmatic individuals. The bronchodilatory effect of XC8 demon-
strated in animals needs to be confirmed in asthmatic individuals [10].
Similarly, the possible effect of XC8 on PBE should be reassessed in
further studies with patients who are asthmatics and have elevated
baseline levels of PBE. The PD data from this study cannot predict the
mechanisms or effect of XC8 on patients with asthma. Furthermore, the
results may not necessarily reflect the safety profile or PK in other
ethnicities as all subjects were Caucasian.
The majority of pharmacological interventions recommended as
controller therapy for adult mild and moderate asthmatic patients are
administered via inhaler [1]. Inhalation therapies in asthma generally
have a very beneficial safety profile [11,12]. However, despite educa-
tional tools seeking to improve inhaler adherence, it remains low [13].
An orally administered anti-asthmatic drug with an adequate safety
profile could be a viable alternative for some patient groups.
XC8 was well tolerated and safe in healthy volunteers. Studies in-
vestigating XC8 in asthmatic patients are currently being performed.
Fig. 1. Mean plasma concentration-time curves of XC8 after single dosing (Day 1, A) and multiple dosing (Day 21, B) of the study medication. Placebo: N=8; 10mg
XC8: N=6; 50mg XC8: N=6; 200mg XC8 N=12; N: number of subjects.
Table 4
Summary of Pharmacokinetic data for XC8.
Geometric mean (CV [%])
Parameter Day 10mg XC8 (N=6) 50mg XC8 (N=6) 200mg XC8 (N=12)
AUC0-24 [h·ng/mL] 1 290 (42.5) 1929 (26.9) 7013 (26.2) b
21 284 (25.1) 1674 (31.9) c 8228 (21.7)
AUC0-tlast [h·ng/mL] 1 290 (42.5) 1929 (26.9) 6461 (29.4)
21 284 (25.1) 1818 (35.5) 8228 (21.7)
AUCinf [h·ng/mL] 1 407 (12.9) a 1706 (8.3) a 6324 (28.4) d
21 344 (8.7) b 1815 (37.6) b 7729 (17.3) d
Cmax [ng/mL] 1 114 (25.5) 626 (20.2) 1993 (26.3)
21 115 (20.9) 552 (30.6) 2089 (17.7)
Cav [ng/mL] 21/1 11.8 (25.1) 69.8 (31.9) c 343 (21.8)
RAUC0-24 21/1 0.98 (24.9) 0.92 (10.0) c 1.14 (14.3) b
RAUCinf 21/1 0.88 (21.4) b NE d 1.15 (17.2) e
RCmax 21/1 1.01 (8.7) 0.88 (28.1) 0.99 (20.1)
Median (range)
t1/2 [h] 1 1.78 (1.56–2.07) a 1.86 (1.59–3.79) a 4.26 (3.86–6.43) d
21 1.66 (1.24–2.23) b 1.89 (1.76–4.89) b 4.55 (3.08–6.15) d
tmax [h] 1 0.83 (0.67–1.00) 0.68 (0.33–1.00) 1.01 (0.67–2.02)
21 0.82 (0.33–2.00) 0.67 (0.32–2.03) 0.98 (0.33–2.00) c
Kel [1/h] 1 0.39 (0.34–0.44) a 0.37 (0.18–0.44) a 0.16 (0.11–0.18) d
21 0.42 (0.31–0.56) b 0.37 (0.14–0.39) b 0.15 (0.11–0.23) d
As all data in the placebo group are NE or zero, the group is not shown.
AUC0-24= area under the plasma concentration curve up to 24 h after the last study drug administration,AUC0-tlast = area under the plasma concentration curve up
to last sampling time with concentration above the limit of quantification, AUCinf = area under the plasma concentration curve extrapolated to infinity,
Cav= average concentration over one dosing interval, Cmax=maximum plasma concentration, CV= coefficient of variation, Kel = elimination rate, N=number of
subjects, NE=not estimable, R= accumulation ratio, SD= standard deviation,t1/2= elimination half-life, tmax= time to Cmax.
a N=2 missing. b N=3 missing. c N=1 missing. d N=4 missing. e N=6 missing.
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CI= confidence interval, Cmax=maximum plasma concentration,
PK= pharmacokinetic.
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